HCM Latest News, Press Relases and Analysis

All

Press Releases

13 hours ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

13 hours ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

3 days ago - By: Virtual Investor Conferences - Mentions: LSE - YRD BLTE ...

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

3 months ago - By: Zacks Investment Research - Mentions: MC CENX

Best Momentum Stock to Buy for August 19th

3 months ago - By: Benzinga - Mentions: GSAT PGY ADV REAL ...

Earnings Scheduled For August 7, 2025

4 days ago - By: Virtual Investor Conferences - Mentions: LSE - YRD BLTE ...

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

12 days ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

12 days ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

20 days ago - By: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

20 days ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

21 days ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

21 days ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

a month ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

a month ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

2 months ago - By: Benzinga - Mentions: QMMM SERV FUN WBD ...

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday

2 months ago - By: HUTCHMED (China) Limited

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

2 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces Appointment of Acting Chief Executive Officer

2 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces Appointment of Acting Chief Executive Officer

3 months ago - By: HUTCHMED (China) Limited

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

3 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Reports 2025 Interim Results

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED to Announce 2025 Half-Year Financial Results

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED to Announce 2025 Half-Year Financial Results

4 months ago - By: HUTCHMED (China) Limited

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

4 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

5 months ago - By: Zacks Investment Research

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

5 months ago - By: Stocktwits - Mentions: LLY

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

5 months ago - By: HUTCHMED (China) Limited - Mentions: LSE -

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

5 months ago - By: HUTCHMED (China) Limited

HUTCHMED CHINA-ADR (HCM) Stock News

HCM Latest News, Press Relases and Analysis

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

HUTCHMED Highlights Pipeline and Business Progress at R&D Updates Event

CORRECTION -- International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

Best Momentum Stock to Buy for August 19th

Earnings Scheduled For August 7, 2025

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 04, 2025

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

HUTCHMED Highlights HMPL-A251 Data Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committee

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights FRUSICA-2 Registration Trial Data to be Presented at the 2025 ESMO Congress

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

IBEX, Tesla, IonQ, Warner Bros. Discovery And Other Big Stocks Moving Higher On Friday

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HUTCHMED Reports 2025 Interim Results

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED to Announce 2025 Half-Year Financial Results

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

HUTCHMED Announces China Approval for ORPATHYS® in Combination with TAGRISSO® for the Treatment of Lung Cancer Patients with MET Amplification After Progression on First-Line EGFR Inhibitor Therapy

Wall Street Analysts See a 68.3% Upside in HUTCHMED (HCM): Can the Stock Really Move This High?

Hutchmed Stock Hits Over One-Month High After China Accepts Kidney Cancer NDA Filed With Partner Innovent Biologics

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights SACHI Phase III Study Data Presented at the 2025 ASCO Annual Meeting

HUTCHMED Highlights Clinical Data to be Presented at the 2025 ASCO Annual Meeting